News
Video
Upcoming Research Related to DLX-001 for Major Depressive Disorder
Author(s):
Key Takeaways
- DLX-001 is a novel neuroplastogen under investigation for treating major depressive disorder (MDD).
- Phase 1 study in healthy volunteers is complete; phase 1b translational study results are expected by mid-2025.
Want to stay in the loop on the latest novel neuroplastogen for major depressive disorder, DLX-001? Check out this update.
Aaron Koenig, MD, the chief medical officer of Delix Therapeutics, shares what you should be on the lookout for related to the novel neuroplastogen, DLX-001, currently under study for patients with MDD.
Researchers have completed the phase 1 study in healthy volunteers. Now, they will begin further research to confirm this potential treatment's effectiveness.
- Delix has started dosing in a single-site, phase 1b translational study. Results will be shared mid 2025.
- Also around mid 2025, researchers will start the phase 2 randomized controlled trial in patients with MDD at multiple sites.
See more on DLX-001 from Dr Koenig here.
Dr Koenig currently serves as chief medical officer for Delix Therapeutics, is a diplomate of the American Board of Psychiatry and Neurology, and retains active board certification in adult and geriatric psychiatry.
Newsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.
